Foghorn Therapeutics reports 2025 net loss $74.3M, cash runway into H1 2028; pipeline advances

Foghorn Therapeutics Inc.

Net loss improved to $74.3M in 2025 from $86.6M in 2024; collaboration revenue rose to $30.9M.
Cash, equivalents, and marketable securities $158.9M at Dec 31, 2025; extended runway into H1 2028 after $50M Jan 2026 financing.
Ryan Maynard appointed CFO in Feb 2026, bringing over 25 years of biopharma finance experience.
Lead candidate FHD-909 Phase 1 dose-escalation on track; collaboration with Lilly advancing.
Selective CBP and EP300 degrader programs on track for IND-enabling studies in 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Foghorn Therapeutics Inc. reported financial results for year ended December 31, 2025.

Period: year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 11, 2026, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-016805

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.